Loading...
•
Dec 31, 2019
Wave Life Sciences Q4 2019 Earnings Report
Wave Life Sciences reported financial results for Q4 2019 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $56.8 million in the fourth quarter of 2019, compared to a net loss of $37.9 million in the same period in 2018. The increase in net loss was primarily driven by increased research and development efforts and continued organizational growth.
Advanced CNS-focused pipeline of stereopure oligonucleotides.
Initiated dosing in a 32 milligram (mg) dose cohort in the PRECISION-HD2 Phase 1b/2a clinical trial of WVE-120102 in January 2020.
Expect to initiate clinical development for SNP3 and C9orf72 programs in 2H 2020.
Presented proof-of-concept data for RNA-editing program in January, expecting initial in vivo results in 2020.
Forward Guidance
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from existing collaborations, will enable Wave to fund its operating and capital expenditure requirements into the third quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...